NEOG

Business Context and Reporting Period

Company: Neogen Corporation (NEOG)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended May 31, 2025
Business Overview: Neogen develops, manufactures, and markets products for food and animal safety. Operations are divided into two segments: Food Safety (diagnostic test kits, culture media, software) and Animal Safety (veterinary instruments, pharmaceuticals, genomics, rodent/insect control). The company completed a significant transaction in September 2022 combining with 3M's Food Safety Division (FSD). In April 2025, the company announced an agreement to sell its global Cleaners and Disinfectants business.

Key Financial Metrics

Note: Dollar amounts in millions unless otherwise noted. Fiscal 2025 results include a non-cash goodwill impairment charge of $1,059.3 million.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 3.2% year-over-year. The decline was driven by a $24.3 million unfavorable foreign exchange impact, $3.9 million from discontinued product lines, and operational headwinds including production constraints in sample collection products and weakness in the companion animal genomics market.
• Goodwill Impairment: The company recorded a massive non-cash goodwill impairment charge of $1,059.3 million. This was triggered by integration challenges with the 3M FSD business and deteriorating end-market conditions. The charge was split between the Food Safety reporting unit ($1,045.3 million) and Animal Safety reporting unit ($13.1 million).
• Margin Compression: Gross margin declined from 50.2% to 47.1%. Contributing factors included lower volume, higher manufacturing costs for sample collection products, elevated inventory write-offs (due to inventory build-up from prior ERP implementation delays), and tariff impacts.
• Segment Performance:
  • Food Safety: Revenue decreased 3% to $638.1 million. Operating loss was $985.7 million, primarily due to the goodwill impairment.
  • Animal Safety: Revenue decreased 5% to $256.5 million. Operating income dropped 82% to $7.2 million due to lower sales and restructuring charges.

Guidance, Outlook, Risks, and Unusual Items

• Management Commentary: Management cited ongoing integration challenges with the 3M FSD business, including manufacturing inefficiencies and ERP implementation delays that caused shipment backlogs in the prior year. While fulfillment issues were largely resolved, the company experienced lost market share and inventory write-offs in FY2025. Tariffs and geopolitical conflicts (Russia-Ukraine, Middle East) continue to impact costs and demand.
• Unusual Items:
  • Goodwill Impairment: $1,059.3 million charge.
  • Restructuring: $11.1 million in restructuring charges, primarily related to the genomics business.
  • Inventory Write-offs: Elevated levels due to inventory build-up from prior year delays.
• Material Weaknesses in Internal Controls: The company identified material weaknesses in internal control over financial reporting. Specifically, management failed to maintain effective review controls over goodwill valuation assumptions and did not consistently retain documentation to support internal control functions. The auditor issued an adverse opinion on internal controls.
• Liquidity and Debt: The company refinanced its credit facilities in April 2025, lowering the interest spread. As of May 31, 2025, the company had $150 million available under its revolving credit facility. Proceeds from the pending sale of the Cleaners & Disinfectants business ($130 million) are expected to be used to repay debt in FY2026.
• Risks: Key risks include the successful integration of the 3M FSD business, realization of synergies, impact of tariffs and trade policies, supply chain disruptions, and the ability to remediate internal control weaknesses.

Investor Verification Checklist

• Goodwill Impairment Methodology: Verify the assumptions used in the discounted cash flow analysis for the $1.06 billion impairment charge, specifically regarding revenue growth rates and discount rates.
• Internal Control Remediation: Review the specific steps management is taking to remediate the material weaknesses in internal controls, particularly regarding goodwill valuation and documentation retention.
• 3M Integration Progress: Assess the timeline and cost associated with the transition of manufacturing operations from 3M to Neogen facilities and the resolution of ERP-related inefficiencies.
• Cleaners & Disinfectants Divestiture: Confirm the closing date and final proceeds of the sale to Kersia Group, and the impact on future revenue and debt reduction.
• Inventory Levels: Monitor inventory turnover and write-off trends to ensure the elevated write-offs in FY2025 were a one-time event related to the ERP transition.